Researchers from Uppsala University and KTH Royal Institute of Technology have developed a pioneering antibody with the potential to treat various forms of cancer. This innovative antibody integrates three key functions into one treatment, enhancing T-cell activity against tumors. The “3-in-1 design” targets cancer cells, delivers a drug directly to them, and simultaneously stimulates the immune system.

The antibody works by redirecting the immune system to identify and attack neoantigens, specific mutations found only in cancer cells. It achieves this by not only delivering tumor-specific material to immune cells but also activating them, significantly boosting T-cell responses. The method has shown positive results, activating immune cells in human blood samples and extending survival in animal models, with higher doses even curing some mice of cancer. The method is also considered safer than previous cancer treatments.

Professor Sara Mangsbo of Uppsala University, the lead author of the study, highlighted that the research demonstrates the antibody’s potential as a precision medicine for cancer. The treatment is also easier and cheaper to produce. The antibody consists of two components: a bispecific antibody that can be mass-produced and a custom peptide that is quickly synthesized for each patient’s cancer type. This streamlined process should expedite treatment, making it more accessible to patients.

The next phase of research involves optimizing the production process, followed by safety studies and clinical trials in humans. The goal is to provide a flexible, faster, and safer cancer treatment that can be customized for individual patients, enhancing their immune response against the disease.